Live, Attenuated, Tetravalent Butantan-Dengue Vaccine in Children and Adults.
Esper G KallásMonica A T CintraJosé A MoreiraElizabeth G PatiñoPatricia Emilia BragaJuliana C V TenórioVanessa InfanteRicardo PalaciosMarcus Vínicius Guimarães de LacerdaDhelio Batista PereiraAllex Jardim da FonsecaRicardo Queiroz GurgelIvo Castelo-Branco CoelhoCor Jesus Fernandes FontesErnesto T A MarquesGustavo Adolfo Sierra RomeroMauro Martins TeixeiraAndré M SiqueiraAldina Maria Prado BarralViviane Sampaio BoaventuraFabiano RamosErivaldo Elias JúniorJosé Cassio de MoraesDimas T CovasJorge KalilAlexander Roberto PreciosoStephen S WhiteheadAlejandra Esteves-JaramilloTulin ShekarJung-Jin LeeJulieta MaceySabrina Gozlan KelnerBeth-Ann G CollerFernanda Castro BoulosMauricio Lacerda NogueiraPublished in: The New England journal of medicine (2024)
A single dose of Butantan-DV prevented symptomatic DENV-1 and DENV-2, regardless of dengue serostatus at baseline, through 2 years of follow-up. (Funded by Instituto Butantan and others; DEN-03-IB ClinicalTrials.gov number, NCT02406729, and WHO ICTRP number, U1111-1168-8679.).